AZ-Pfizer relief: 'at risk' partnerships in the clear as takeover plans fold
This article was originally published in Scrip
Executive Summary
As the news breaks that UK big pharma AstraZeneca has rejected a final takeover bid from US giant Pfizer, several of both the firms' smaller pharma and biotech partners will be breathing a sigh of relief.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.